Mega Consolidation: SeQuent Scientific and Viyash Lifesciences backed by PE Carlyle Group
M & A Critique|November 2024
SeQuent Scientific Limited announced a merger which is expected to create a unique & differentiated platform with leading market position in Animal healthcare segment.
Anirudha Jain
Mega Consolidation: SeQuent Scientific and Viyash Lifesciences backed by PE Carlyle Group

SeQuent Scientific Limited ("SEQUENT" or "SSL" or "Amalgamated Company"), headquartered in India, operates in Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from various international regulatory bodies. SeQuent currently produces APIs and Animal health formulations in over 100 countries and has more than 1,500 employees. The equity shares of SSL are listed on nationwide bourses. In 2020, The Carlyle Group acquired controlling stake in SSL giving complete exit to erstwhile promoters.

Other company of SSL involved in the proposed transaction is SeQuent Research Limited ("SRL" or Amalgamating Company 2") which is wholly owned subsidiary of SSL.

Viyash Lifesciences (together with various companies as mentioned hereinafter) is an integrated end-to-end pharmaceutical company with a presence across niche formulations, APIs and advanced intermediates. Viyash has an R&D team of 200+ scientists and has 9 USFDA approved plants, signifying strong R&D and manufacturing capabilities.

Viyash serves customers across 150+ countries. List of companies pertaining to Viyash Lifesciences involved in the transaction is as follow:

Viyash Life Sciences Private Limited ("VLSPL" or Transferee Company 1" or Amalgamating Company 1). The company is engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients. The Company is a holding company for all other Viyash group companies.

• Symed Labs Limited ("SLL" or Transferor Company 1") is a wholly owned subsidiary of VLSPL. The company is engaged in manufacturing of bulk drug and intermediates.

Bu hikaye M & A Critique dergisinin November 2024 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

Bu hikaye M & A Critique dergisinin November 2024 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

M & A CRITIQUE DERGISINDEN DAHA FAZLA HIKAYETümünü görüntüle
Cement Sector Consolidation Continues: Orient Cement to be acquired by Adani Group's Ambuja Cement
M & A Critique

Cement Sector Consolidation Continues: Orient Cement to be acquired by Adani Group's Ambuja Cement

The shopping spree for the Adani group seems to be unstoppable. Recently, Adani group announced yet another acquisition in the cement space. This time it is Orient Cement Limited.

time-read
3 dak  |
November 2024
ITAT held that the reserve created on amalgamation is capital in nature and not taxable as perquisite
M & A Critique

ITAT held that the reserve created on amalgamation is capital in nature and not taxable as perquisite

Recently, the Income Tax Appellate Tribunal, Mumbai held that the reserve created on amalgamation is capital in nature and not taxable as perquisite.

time-read
4 dak  |
November 2024
Mega Consolidation: SeQuent Scientific and Viyash Lifesciences backed by PE Carlyle Group
M & A Critique

Mega Consolidation: SeQuent Scientific and Viyash Lifesciences backed by PE Carlyle Group

SeQuent Scientific Limited announced a merger which is expected to create a unique & differentiated platform with leading market position in Animal healthcare segment.

time-read
7 dak  |
November 2024
Raymond Group continues Segregation of its Business Verticals
M & A Critique

Raymond Group continues Segregation of its Business Verticals

After successful demerger of \"Lifestyle Business,\" Raymond Limited announced yet another restructuring to unlock further value for stakeholders.

time-read
3 dak  |
August 2024
Ultratech Cements adds India Cement in its shopping cart
M & A Critique

Ultratech Cements adds India Cement in its shopping cart

India's Cement Industry is poised for consolidation. In recent past we have seen multiple large & small acquisitions in cement segment for consolidating positions.

time-read
3 dak  |
August 2024
Valor Estate Limited: "Diversification" to "Sepration" of Hospitality Business
M & A Critique

Valor Estate Limited: "Diversification" to "Sepration" of Hospitality Business

“From investments in hospitality business, the demerger transaction will enable VEL to start its construction in hospitality”

time-read
4 dak  |
August 2024
SIEMENS Energy to be a separate entity in alignment with global strategy
M & A Critique

SIEMENS Energy to be a separate entity in alignment with global strategy

Siemens AG announced its Vision 2020+ which included the spin-off of its Gas & Power [G&P) i.e., Energy Business into Siemens Energy.

time-read
5 dak  |
June 2024
Arvind Group separates its Advanced Material Business for independent growth trajectory
M & A Critique

Arvind Group separates its Advanced Material Business for independent growth trajectory

Advanced Material Business (AMD) of Arvind Limited focuses on advanced materials and caters to customer needs across the textile value chain, including specialty yarns, fabrics, and ready-made products.

time-read
3 dak  |
June 2024
Merger for bail-out from debt obligation
M & A Critique

Merger for bail-out from debt obligation

Ind Swift Limited (herein after also referred to as 'ISL' or 'Transferor Company') is engaged in the business of manufacturing of Pharmaceutical Products.

time-read
3 dak  |
June 2024
Batliboi Ltd. merging its associate company
M & A Critique

Batliboi Ltd. merging its associate company

Batliboi Limited has a history of collaborations with various foreign technical partners and has subsidiaries like Hydraulic & General Engineers Ltd. and Batliboi International Ltd. In March 2024, the board of Directors of Batliboi Limited accorded their approval for the merger of promoter owned private company with itself.

time-read
2 dak  |
May 2024